At the conference, Acuitas' Chief Scientific Officer, Dr. Ying Tam, showcased the company's Next-Generation LNP advancements, a comprehensive approach that uses multiple technologies and strategies to ...
Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...
The study was published in Nature Biotechnology last month and marks a shift in scientists’ understanding of how to ...
Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in ...
Researchers at University of Tsukuba have achieved high-resolution visualization of cellular organelles, such as nuclei and ...
Biomedical research typically follows a familiar path: developing treatments that block, enhance or mutate certain signaling pathways, genes or proteins to change the function of different cells in ...
A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.
Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...
A new delivery particle developed at MIT could make mRNA vaccines more effective and potentially lower the cost per vaccine ...
The team used the AMG1541 LNP to deliver an mRNA influenza vaccine in mice. They compared this vaccine’s effectiveness to a flu vaccine made with the lipid SM-102, which is FDA-approved and was used ...
A new lipid nanoparticle could make mRNA vaccines more effective and potentially lower the cost per dose. New research suggests an mRNA influenza vaccine delivered with the new particle could generate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback